1. Scrip
  2. >>Business

Pfizer, Allergan In Third-Biggest Merger Ever

 
• By Eleanor Malone

Pfizer and Allergan have announced their much-anticipated merger, agreeing a $160bn deal that will be the world's third biggest corporate deal ever, after AOL/Time Warner and Vodafone/Mannesmann. The deal is by far the biggest healthcare transaction in history; the previous largest was also completed by Pfizer (when it bought Warner-Lambert for $90bn 15 years ago).

Pfizer and Allergan have announced their much-anticipated merger, agreeing a $160bn deal that will be the world's third biggest corporate deal ever, after AOL/Time Warner and Vodafone/Mannesmann. The deal is by far the biggest healthcare transaction in history; the previous largest was also completed by Pfizer (when it bought Warner-Lambert for $90bn 15 years ago).

On a conference call in which Pfizer CEO and CFO Ian Read and Frank D'Amelio and Allergan CEO Brent Saunders took questions from analysts, the key message was that...

More from Business

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

More from Scrip

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.